Tina supports the Tullis investment process at multiple levels including deal sourcing, deal review, due diligence, and investment management. Tina is an inventor on numerous scientific patents, and currently serves as president of Veracyte’s CLIA U.S. business as well as chair of the board of directors at Arena Pharmaceuticals (Nasdaq: ARNA). Prior to joining Tullis, she was chief executive officer and president of Genoptix, a Tullis portfolio company she co-founded in 2000 and took public on the NASDAQ. She is a former chair of the board of directors of BIOCOM, a life science association representing over 500 member companies, as well as an Ernst & Young Entrepreneur of the Year Life Science recipient and an Athena Lifetime Award Pinnacle winner.

Tina was previously president and chief executive officer of Decipher Biosciences, Inc., a genomics company focused on the diagnosis of prostate cancer. Before that she was president and CEO of Molecular Stethoscope, Inc., as well as senior vice president and general manager of the oncology business unit of Illumina, Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Tina co-founded Nanogen, Inc., a provider of molecular diagnostic tests, and served as its chief operating officer and president for six years. She also held positions with Ligand Pharmaceuticals, Selective Genetics, and Hybritech.

Tina holds a Bachelor of Science in biological sciences from the University of California, Irvine, where she graduated with honors in research, and a doctorate in biochemistry from the University of California, Riverside.